IL-13 Antibody

ELISA, WB, Neutralization Assay

IL-13 antibody is stable for at least 2 years from date of receipt at -20˚ C. The reconstituted antibody is stable for at least two weeks at 2-8˚ C. Frozen aliquots are stable for at least 6 months when stored at -20˚ C. Avoid repeated freeze-thaw cycles.

L13 inhibits proinflammatory cytokine production and stimulates antibody production. It induces proliferation in the human pre myeloid cell line TF1. IL13 has multiple effects on the differentiation and functions of monocytes and macrophages. It suppresses cytotoxic functions and induces changes in the morphology of human monocytes and in the phenotype of human monocytes and B cells by upregulating MHC class II expression. IL13 will also decrease the production of nitric oxide by activated murine macrophages, leading to impaired parasiticidal activity. Human and mouse interleukin 13 share approximately 58% amino acid sequence identity. Although human and mouse IL13 are equally active on human cells, human IL13 is much less active than mouse IL13 on mouse cells. Human IL13 and human IL4 also share approximately 30% sequence homology and have similar biological functions.

None

Anti-mIL-13 specific antibody was purified by affinity chromatography employing immobilized mIL-13 matrix.

Neutralization:
To yield one-half maximal inhibition [ND50] of the biological activity of Murine IL-13 (10 ng/mL), a concentration of 0.08 - 0.10 μ g/mL of this antibody is required.
ELISA:
To detect mIL-13 by direct ELISA (using 100 μ L/well antibody solution) a concentration of at least 0.5 μ g/mL of this antibody is required. This antigen affinity purified antibody, in conjunction with compatible secondary reagents, allows the detection of 0.2 - 0.4 ng/well of recombinant mIL-13.
Sandwich
To detect mIL-13 by sandwich ELISA (using 100 μ L/well antibody solution) a concentration of 0.5 - 2.0 μ g/mL of this antibody is required. This antigen affinity purified antibody, in conjunction with our Biotinylated Anti-Murine IL-13 (XP-5168Bt) as a detection antibody, allows the detection of at least 0.2 - 0.4 ng/well of recombinant mIL-13.
Western Blot:
To detect mIL-13 by Western Blot analysis this antibody can be used at a concentration of 0.1 - 0.2 μ g/mL. Used in conjunction with compatible secondary reagents the detection limit for recombinant mIL-13 is 1.5 - 3.0 ng/lane, under either reducing or non-reducing conditions.

Polyclonal

Mus musculus

Centrifuge vial prior to opening.